title: The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
abstract: OBJECTIVE
  To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation.
  
  
  METHODS
  Seven EOC cell lines and 110 advanced stage EOC specimens were analyzed for MASPIN promoter methylation. The cell lines were treated with 5-azacytidine (5-azaC) and evaluated for MASPIN promoter methylation, protein, and mRNA expression. Wild-type (wt) p53 was transiently transfected into the mutant p53 (m p53) SKOV3 cells which were treated with 5-azaC. Phosphor imager analysis quantified the percent methylation of the MASPIN promoter.
  
  
  RESULTS
  Of the 3 MASPIN-low m p53 cell lines 2 had greater than 5% MASPIN methylation whereas only 1 of 4 MASPIN-high wt p53 cell lines had greater than 5% MASPIN methylation. Despite the presence of aberrant MASPIN promoter methylation in SKOV3 cells, wt p53-transfection alone resulted in a 3.3-fold increase in MASPIN mRNA. The combination of 5-azaC and wt p53-transfection produced a 36% reduction in MASPIN promoter methylation and 4.5-fold increase in MASPIN transcription. Among the 110 ovarian cancer specimens analyzed for methylation of the MASPIN promoter, 81.8% were weakly methylated, 14.5% were heavily methylated and 3.6% were fully methylated. There was no relationship between promoter methylation and p53 status or MASPIN protein expression. However, MASPIN protein was 6 times more likely to be detected in cancer specimens that harbor a p53 mutation relative to cancer specimens with a wt p53 gene.
  
  
  CONCLUSIONS
  The regulation of MASPIN is a complex multifactorial process that may be controlled by both p53-dependent and -independent epigenetic mechanisms.
authors: Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA. secor002@mc.duke.edu
authors: Angeles
authors: A
authors: Alvarez Secord
authors: Kathleen M
authors: KM
authors: Darcy
authors: Alan
authors: A
authors: Hutson
authors: Zhiqing
authors: Z
authors: Huang
authors: Paula S
authors: PS
authors: Lee
authors: Elizabeth L
authors: EL
authors: Jewell
authors: Laura J
authors: LJ
authors: Havrilesky
authors: Maurie
authors: M
authors: Markman
authors: Franco
authors: F
authors: Muggia
authors: Susan K
authors: SK
authors: Murphy
mesh_terms: D001374:Azacitidine / Q000494:pharmacology; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D019175:DNA Methylation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics*; D011401:Promoter Regions, Genetic; D015843:Serpins / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000502:physiology*
chemical_list: C085344:SERPIN-B5; D015843:Serpins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D001374:Azacitidine